Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

294 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Recommended Adult Immunization Schedule, United States, 2021.
Freedman MS, Bernstein H, Ault KA; Advisory Committee on Immunization Practices. Freedman MS, et al. Ann Intern Med. 2021 Mar;174(3):374-384. doi: 10.7326/M20-8080. Epub 2021 Feb 11. Ann Intern Med. 2021. PMID: 33571011 No abstract available.
Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis: Results from Randomized Phase 2b Core and Extension Studies.
Freedman MS, Pozzilli C, Havrdova EK, Lemle A, Burcklen M, Larbalestier A, Hennessy B, Sidorenko T, Vaclavkova A, Olsson T; onbehalf of Ponesimod Phase II Study Group. Freedman MS, et al. Neurology. 2022 Jun 6:10.1212/WNL.0000000000200606. doi: 10.1212/WNL.0000000000200606. Online ahead of print. Neurology. 2022. PMID: 35667837
Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta-1a.
Battaglini M, Vrenken H, Tappa Brocci R, Gentile G, Luchetti L, Versteeg A, Freedman MS, Uitdehaag BMJ, Kappos L, Comi G, Seitzinger A, Jack D, Sormani MP, Barkhof F, De Stefano N. Battaglini M, et al. Among authors: freedman ms. Eur J Neurol. 2022 Jul;29(7):2024-2035. doi: 10.1111/ene.15314. Epub 2022 Apr 4. Eur J Neurol. 2022. PMID: 35274413 Clinical Trial.
High or increasing serum NfL is predictive of impending multiple sclerosis relapses.
Thebault S, Reaume M, Marrie RA, Marriott JJ, Furlan R, Laroni A, Booth RA, Uccelli A, Freedman MS. Thebault S, et al. Among authors: freedman ms. Mult Scler Relat Disord. 2022 Mar;59:103535. doi: 10.1016/j.msard.2022.103535. Epub 2022 Jan 19. Mult Scler Relat Disord. 2022. PMID: 35078125 Free article. Clinical Trial.
Body mass index as a predictor of MS activity and progression among participants in BENEFIT.
Manuel Escobar J, Cortese M, Edan G, Freedman MS, Hartung HP, Montalbán X, Sandbrink R, Radü EW, Barkhof F, Wicklein EM, Kappos L, Ascherio A, Munger KL. Manuel Escobar J, et al. Among authors: freedman ms. Mult Scler. 2022 Jul;28(8):1277-1285. doi: 10.1177/13524585211061861. Epub 2022 Jan 7. Mult Scler. 2022. PMID: 34994579 Free PMC article.
294 results